Expert Describes How Robotic Device Streamlines Cancer Surgical Process

Commentary
Video

The Epione robot eliminates the need for multiple check scans during surgery by allowing physicians to target a tumor with a single button press, according to Govindarajan Narayanan, MD.

CancerNetwork® spoke with Govindarajan Narayanan, MD, about how Epione, a robotic tool, streamlines ablative surgical procedures for cancer by minimizing the need for certain manual corrections when administering the needle to a patient’s tumor.

Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, both of Baptist Health South Florida, highlighted his methodology prior to the advent of the Epione robot, which involved using CT scans as guidance for manually adjusting the needle’s precision in the middle of ablative surgery. He indicated that planning and executing the procedure becomes simplified with Epione, as a single button press allows physicians to push the needle towards the targeted tumor, thereby reducing patient and operator exposure to radiation that they may experience during standard check scans.

Transcript:

The Epione robot is something that helps us with ablations or needle-based procedures that we do. When we do ablations, we typically use CT scan guidance or ultrasound. As interventional radiologists, we are trained to advance the needles in different planes. You go from the skin to the target, making adjustments to your needle along the way. To go from the skin to the target, you have to plan it; as you go in with the needle, you need to make adjustments. The needle could be a little towards the head or to the feet, or anterior or posterior.

You have to make all those adjustments as you’re doing it. Before Epione, all of this had to be done in your head, and you had to manually make the adjustments. With the Epione robotics system, you plan everything in the workstation of the robot. Once it has plotted the path for you, you can pretty much push the needle from the skin to the target with one push instead of having to do multiple check scans, which involves radiation to the patient and to the operator.

Reference

Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content